Austar Lifesciences Limited
AULSF
$0.07
$0.0651,300.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 113.93% | 114.04% | 114.24% | 114.02% | -298.10% |
| Total Depreciation and Amortization | 9.61% | 10.48% | 29.85% | 27.88% | 52.25% |
| Total Amortization of Deferred Charges | 6.14% | 7.01% | -1.20% | -2.74% | 95.19% |
| Total Other Non-Cash Items | -90.45% | -90.37% | 74.78% | 75.16% | 9.42% |
| Change in Net Operating Assets | 119.29% | 119.44% | -- | -- | 39.17% |
| Cash from Operations | 3,548.74% | 3,576.10% | 129.16% | 128.72% | -72.08% |
| Capital Expenditure | 56.86% | 56.52% | 84.37% | 84.61% | -33.87% |
| Sale of Property, Plant, and Equipment | -19,524.32% | -19,621.62% | 5,300.00% | 5,214.02% | -242.31% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 159.67% | 161.73% | -41.42% | -42.32% | 114.13% |
| Cash from Investing | 72.68% | 72.46% | 147.11% | 146.40% | 55.82% |
| Total Debt Issued | -29.03% | -29.03% | -34.06% | -34.06% | 77.16% |
| Total Debt Repaid | -27.71% | -27.71% | -62.68% | -62.68% | -52.60% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.66% | -9.66% | 44.68% | 44.68% | -90.76% |
| Cash from Financing | -170.25% | -170.81% | -165.79% | -164.80% | 356.02% |
| Foreign Exchange rate Adjustments | 1,520.59% | 1,526.47% | 251.52% | 244.12% | -96.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -28.92% | -28.35% | -197.59% | -193.10% | 188.85% |